Literature DB >> 31467225

EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

James Saller1, Shabnam Seydafkan1, Mohammad Shahid1, Manoj Gadara1, Mauro Cives2, Steven A Eschrich3, David Boulware3, Jonathan R Strosberg2, Nasir Aejaz4, Domenico Coppola5,6,7,8.   

Abstract

BACKGROUND/AIM: Low-grade pancreatic neuroendocrine tumors (LG-PNETs) behave unpredictably. The aim of the study was to identify biomarkers that predict PNET metastasis to improve treatment selection. PATIENTS AND METHODS: Five patients with primary non-metastatic LG-PNETs, six with primary LG-PNETs with synchronous or metachronous metastases (M-PNETs), and six metastatic to liver LG-PNETs (ML-PNETs) from the group of six M-PNET patients were selected. RNA data were normalized using iterative rank-order normalization. Student's t-test identified differentially-expressed genes in LG-PNETs versus M-PNETs. A 2-fold difference in expression was considered to be significant. Results were validated with an independent dataset of LG-PNETs and metastatic LG-PNETs.
RESULTS: Overall, 195 genes had a >2-fold change (in either direction). A total of 29 genes were differentially overexpressed in M-PNETs. Erythrocyte membrane protein band 4.1-like 5 (EPB41L5) had a 2.07-fold change increase in M-PNETs and the smallest p-value. EPB41L5 was not statistically different between M-PNETs and ML-PNETs. EPB41L5 differential expression between primary and metastatic LG-PNETs was confirmed by immunohistochemistry.
CONCLUSION: These results support further investigation into whether EPB41L5 is a biomarker of PNETs with high risk for metastases. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  EPB41L5; Pancreatic neuroendocrine tumor; gene expression profile; immunohistochemistry

Mesh:

Substances:

Year:  2019        PMID: 31467225      PMCID: PMC6727072          DOI: 10.21873/cgp.20136

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  101 in total

1.  Therapy. Aptamer-lipid nanoparticle conjugates for RNAi in bone.

Authors:  Jennifer Sargent
Journal:  Nat Rev Endocrinol       Date:  2015-02-24       Impact factor: 43.330

2.  Whole-genome landscape of pancreatic neuroendocrine tumours.

Authors:  Aldo Scarpa; David K Chang; Katia Nones; Vincenzo Corbo; Ann-Marie Patch; Peter Bailey; Rita T Lawlor; Amber L Johns; David K Miller; Andrea Mafficini; Borislav Rusev; Maria Scardoni; Davide Antonello; Stefano Barbi; Katarzyna O Sikora; Sara Cingarlini; Caterina Vicentini; Skye McKay; Michael C J Quinn; Timothy J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne McLean; Craig Nourse; Ehsan Nourbakhsh; Peter J Wilson; Matthew J Anderson; J Lynn Fink; Felicity Newell; Nick Waddell; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Scott Wood; Qinying Xu; Shivashankar Hiriyur Nagaraj; Eliana Amato; Irene Dalai; Samantha Bersani; Ivana Cataldo; Angelo P Dei Tos; Paola Capelli; Maria Vittoria Davì; Luca Landoni; Anna Malpaga; Marco Miotto; Vicki L J Whitehall; Barbara A Leggett; Janelle L Harris; Jonathan Harris; Marc D Jones; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Adnan M Nagrial; Marina Pajic; Christopher J Scarlett; Andreia Pinho; Ilse Rooman; Christopher Toon; Jianmin Wu; Mark Pinese; Mark Cowley; Andrew Barbour; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Jessica A Lovell; Nigel B Jamieson; Fraser Duthie; Marie-Claude Gingras; William E Fisher; Rebecca A Dagg; Loretta M S Lau; Michael Lee; Hilda A Pickett; Roger R Reddel; Jaswinder S Samra; James G Kench; Neil D Merrett; Krishna Epari; Nam Q Nguyen; Nikolajs Zeps; Massimo Falconi; Michele Simbolo; Giovanni Butturini; George Van Buren; Stefano Partelli; Matteo Fassan; Kum Kum Khanna; Anthony J Gill; David A Wheeler; Richard A Gibbs; Elizabeth A Musgrove; Claudio Bassi; Giampaolo Tortora; Paolo Pederzoli; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2017-02-15       Impact factor: 49.962

Review 3.  Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.

Authors:  Aatur D Singhi; David S Klimstra
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

4.  Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours.

Authors:  Jaihwan Kim; Woo Jin Lee; Sang Hyub Lee; Kyoung Bun Lee; Ji Kon Ryu; Yong-Tae Kim; Sun-Whe Kim; Yong Bum Yoon; Jin Hyeok Hwang; Ho-Seong Han; Sang Myung Woo; Sang Jae Park
Journal:  Dig Liver Dis       Date:  2011-12       Impact factor: 4.088

5.  Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.

Authors:  Chanjuan Shi; David S Klimstra
Journal:  Semin Diagn Pathol       Date:  2014-09-30       Impact factor: 3.464

6.  Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.

Authors:  Irvin M Modlin; Steven F Moss; Daniel C Chung; Robert T Jensen; Elizabeth Snyderwine
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

7.  Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.

Authors:  Luis Jaime Castro-Vega; Eric Letouzé; Nelly Burnichon; Alexandre Buffet; Pierre-Hélie Disderot; Emmanuel Khalifa; Céline Loriot; Nabila Elarouci; Aurélie Morin; Mélanie Menara; Charlotte Lepoutre-Lussey; Cécile Badoual; Mathilde Sibony; Bertrand Dousset; Rossella Libé; Franck Zinzindohoue; Pierre François Plouin; Jérôme Bertherat; Laurence Amar; Aurélien de Reyniès; Judith Favier; Anne-Paule Gimenez-Roqueplo
Journal:  Nat Commun       Date:  2015-01-27       Impact factor: 17.694

8.  Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix.

Authors:  Leila Akkari; Vasilena Gocheva; Jemila C Kester; Karen E Hunter; Marsha L Quick; Lisa Sevenich; Hao-Wei Wang; Christoph Peters; Laura H Tang; David S Klimstra; Thomas Reinheckel; Johanna A Joyce
Journal:  Genes Dev       Date:  2014-10-01       Impact factor: 11.361

9.  Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Authors:  Timothy J Hobday; Rui Qin; Diane Reidy-Lagunes; Malcolm J Moore; Jonathan Strosberg; Andreas Kaubisch; Manisha Shah; Hedy Lee Kindler; Heinz-Josef Lenz; Helen Chen; Charles Erlichman
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 50.717

Review 10.  Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Authors:  Inbal Uri; Simona Grozinsky-Glasberg
Journal:  Clin Diabetes Endocrinol       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.